Evidence map›Paper›PMID 27624670›Full record

ArticleLeukemia2017

A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.

A K Burnett, N H Russell, R K Hills, J Kell, O J Nielsen, M Dennis, P Cahalin, C Pocock, S Ali, S Burns and 3 more

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03992352 (Composite Health Assessment Risk Model), which is not on this map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03992352 completednot on this mapstarted 2019, after this paper: background citation

Composite Health Assessment Risk Model (CHARM) for Older Adults: Applying Pre-Transplant Comorbidity, Geriatric Assessment, and BioMarkers on Non-Relapse Mortality After Allogeneic Transplant (BMT CTN 1704)

TypeobservationalSponsorCenter for International Blood and Marrow Transplant ResearchRan2019 to 2023Enrolled1,229ConditionsHematologic MalignancyArmsAge 60+ with planned HCT for Hematologic Malignancy
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 30 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Aging: Treating the Older Patient.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017
    Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 2 countries.

A K BurnettDepartment of Haematology, Cardiff University School of Medicine, Cardiff, UK.
N H RussellDepartment of Haematology, Nottingham University Hospital NHS Trust, Nottingham, UK.
R K HillsCentre for Trails Research, Cardiff University, Cardiff, UK.
J KellDepartment of Haematology, University Hospital of Wales Cardiff, Cardiff, UK.
O J NielsenDepartment of Haematology, Rigshospitalet, Copenhagen, Denmark.
M DennisDepartment of Haematology, Christie Hospital, Manchester, UK.
P CahalinDepartment of Haematology, Blackpool Victoria Hospital, Blackpool, UK.
C PocockDepartment of Haematology, Kent & Canterbury Hospital, Canterbury, Kent, UK.
S AliDepartment of Haematology, Castle Hill Hospital, Hull, UK.
S BurnsCentre for Trails Research, Cardiff University, Cardiff, UK.
S FreemanDepartment of Immunology, University of Birmingham, Birmingham, UK.
D MilliganDepartment of Haematology, Heartlands Hospital, Birmingham, UK.
R E ClarkDepartment of Haematology, Royal Liverpool University Hospital, Liverpool, UK.
University of Liverpool · GBCardiff University · GBCastle Hill Hospital · GBNottingham University Hospitals NHS Trust · GBUniversity Hospital of Wales · GBHeartlands Hospital · GBRigshospitalet · DK

Funding

Cancer Research UK 15954
6 · The paper itself

Abstract

The study was designed to compare clofarabine plus daunorubicin vs daunorubicin/ara-C in older patients with acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). Eight hundred and six untreated patients in the UK NCRI AML16 trial with AML/high-risk MDS (median age, 67 years; range 56-84) and normal serum creatinine were randomised to two courses of induction chemotherapy with either daunorubicin/ara-C (DA) or daunorubicin/clofarabine (DClo). Patients were also included in additional randomisations; ± one dose of gemtuzumab ozogamicin in course 1; 2v3 courses and ± azacitidine maintenance. The primary end point was overall survival. The overall response rate was 69% (complete remission (CR) 60%; CRi 9%), with no difference between DA (71%) and DClo (66%). There was no difference in 30-/60-day mortality or toxicity: significantly more supportive care was required in the DA arm even though platelet and neutrophil recovery was significantly slower with DClo. There were no differences in cumulative incidence of relapse (74% vs 68%; hazard ratio (HR) 0.93 (0.77-1.14), P=0.5); survival from relapse (7% vs 9%; HR 0.96 (0.77-1.19), P=0.7); relapse-free (31% vs 32%; HR 1.02 (0.83-1.24), P=0.9) or overall survival (23% vs 22%; HR 1.08 (0.93-1.26), P=0.3). Clofarabine 20 mg/m

Indexed as

Adenine NucleotidesAgedAged, 80 and overAge FactorsAntineoplastic Combined Chemotherapy ProtocolsArabinonucleosidesCause of DeathClofarabineCytarabineDaunorubicinFemaleHumansInduction ChemotherapyLeukemia, Myeloid, AcuteMaleMiddle AgedAdenine NucleotidesArabinonucleosidesClofarabineCytarabineDaunorubicin

Identifiers

PMID27624670
PMCPMC5292678
OpenAlexW2514457780

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.